得益于北京市近日发布的两项"AI+医疗健康"政策，北京市海淀区甘家口社区卫生服务中心的AI诊疗能 力可能再上台阶；鹰瞳科技这家做眼底病变大数据模型的企业将有机会和医疗机构合作，获得更好的落 地场景。 这两项政策分别是《北京市支持医疗健康领域人工智能应用发展行动计划（2026-2027年）》（以下简 称《行动计划》）和《北京市医疗健康领域支持人工智能产业创新发展若干措施（2026-2027年）》 （以下简称《若干措施》）。 在苏文看来，数据是人工智能发展的基础。北京的新政提出要强化数据治理，释放要素价值。相关的举 措包括，加快北京全民健康信息平台建设，整合各类医疗数据，为企业提供高质量的数据集。同时，新 政制定数据脱敏和标注规范，保障数据安全，促进数据流通交易，这将极大提升企业获取和使用高质量 数据的效率。 另外，苏文注意到，新政鼓励企业与医疗机构开展深度交流对接，形成供需对接机制。政策还明确要开 放多元化试点应用场景，她说，这将有助于企业更好地理解临床需求，优化算法模型，实现与医疗机构 的高效配合。 铂生卓越是致力于干细胞药物研究及临床转化与应用的创新药企业，其核心产品艾米迈托赛注射液是我 国第一款获批上市的 ...

中青报·中青网记者 刘世昕 得益于北京市12月30日发布的两项医疗健康+AI政策，北京市海淀区甘家口社区卫生服务中心的AI诊疗 能力近期可能再上台阶；鹰瞳科技这家做眼底病变大数据模型的企业将有更畅通的机会和医疗机构合 作，获得更好的落地场景。 这两项政策分别是《北京市支持医疗健康领域人工智能应用发展行动计划（2026-2027年）》（以下简 称《行动计划》）和《北京市医疗健康领域支持人工智能产业创新发展若干措施（2026-2027年）》 （以下简称《若干措施》）。 《行动计划》明确，到2027年，北京的人工智能技术在疾病防、筛、管、救、治、康全流程得到广泛应 用，全市医疗卫生机构普遍开展人工智能产品落地应用，百姓将享有更优质的医疗服务。《若干措施》 则从聚焦临床需求场景、强化数据治理、优化支撑体系、强化政策保障4个维度出发，锚定到2027年， 北京在医疗健康领域建成"需求精准对接、数据高效流通、技术快速转化、生态协同发展"的人工智能产 业支撑体系。 《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》提出，全面实施"人工智能+"行 动，加强人工智能同产业发展、文化建设、民生保障、社会治理相结合，全方位 ...

"我一晚没睡，挣的钱都给美容院了。" 两年前，周进发现妻子程璐有笔20万元异常转账，细查之下更感震惊——7年时间，管理家中财务的妻 子竟为所谓"干细胞美容"陆续花费超2000万元。这场始于"高科技护肤"的消费，最终将夫妻二人推上诉 讼之路。今年12月初，二审宣判认定美容院老板存在无资质行医、使用"干细胞"不规范宣传等行为，但 未认定构成欺诈，最终判处退回450余万元。周进决定申请再审，并继续向有关部门举报。 而在个体悲剧背后，一个更广阔的市场乱象正浮出水面：干细胞虽在医学领域展现出修复与分化的潜 力，但近年来，"干细胞美容"俨然成为美容行业的热门标签，从外涂面霜、口服胶囊到直接注射，产品 只要与"干细胞"沾边，便仿佛镀上了一层"神奇"光环。 针对这一乱象，12月5日国家卫生健康委新闻发言人胡强强在新闻发布会上明确强调：干细胞等细胞与 基因治疗必须由具备资质的专业医疗机构开展，美容院、养生馆等非医疗机构不具备资质，不得开展任 何诊疗活动。 随着监管声音的落地与个案诉讼的推进，一场关于干细胞美容虚假宣传与行业规范的公众讨论，正悄然 拉开帷幕。 20万一针"抗衰"还"抗癌"？ 天价账单下的"干细胞美容"幻梦 面对一 ...

Core Viewpoint - OriCell, a subsidiary of Saiye, focuses on cell biology and stem cell technology services, emphasizing the importance of mesenchymal stem cells (MSC) in regenerative medicine and their growing application in clinical trials [2][10]. Group 1: MSC Research and Development - MSCs have unique differentiation potential and immune regulation capabilities, making them a key focus in regenerative medicine [2]. - The National Medical Products Administration (NMPA) has approved nearly 200 clinical trial applications for stem cell products, with the first MSC therapy, "Aimi Maitosai Injection," set to launch in early 2025 for treating hormone-refractory acute graft-versus-host disease [2]. - The application boundaries of MSCs are expanding, serving as a crucial bridge between basic research and clinical translation [2]. Group 2: Research Support and Resources - OriCell has compiled a research guide titled "Mesenchymal Stem Cells: Cultivation and Tri-lineage Induction," aimed at both newcomers and experienced research teams to provide practical technical support [3]. - The guide offers a systematic framework of MSC knowledge, detailing definitions, characteristics from different sources, and biological functions to help establish foundational understanding [5]. - It includes standardized operational processes, breaking down key procedures such as cell passage digestion time, cryopreservation points, and recovery plating density, along with tri-lineage induction steps and identification methods [5]. Group 3: Practical Solutions and Optimization - The guide provides practical solutions to common experimental challenges, analyzing factors like serum quality and culture temperature, and offering validated optimization strategies to avoid typical pitfalls in experiments [5]. - OriCell aims to enhance the confidence in MSC cultivation and induction processes, supporting researchers in overcoming experimental difficulties [7].

本报记者 张敏 许林艳 近年来，"干细胞"凭借自我更新与多向分化的核心潜能，已成为全球医学领域的研究热点。今年1月份，我国首款干细胞 治疗药品艾米迈托赛注射液上市。这标志着我国干细胞药物进入商业化阶段。 "2025年可以被定义为干细胞转化应用的元年，因为在这一年，我国首款干细胞新药上市，海南博鳌乐城干细胞收费治 疗，多地密集出台细胞与基因治疗推进政策，国家监管步入统一全流程监管阶段。"云南省细胞治疗技术转化医学重点实验室 主任、云南省成体干细胞治疗技术创新团队带头人潘兴华向《证券日报》记者表示。 清华大学生物医学工程学院长聘教授、副院长杜亚楠预测，未来几年，干细胞治疗的临床试验规模将继续扩大，相关新药 上市数量将增多，适应症范围也将不断拓展。 干细胞治疗何以发展壮大 传统药物大多旨在缓解症状或控制病情发展，而干细胞治疗的目标是修复、替换或再生受损的细胞、组织和器官，试图从 根源上解决疾病问题。它的应用领域涵盖了多个现代医学的难题，比如阿尔茨海默病、疾病或衰老造成的组织损伤等。 "最近30年来，干细胞治疗技术取得了诸多突破性进展，特别是诺贝尔奖级别的成果助推了干细胞治疗技术的发展，其中 核移植、人类胚胎干细胞建 ...

Core Insights - The "惠民保" (Huimin Insurance) has expanded its coverage to include chronic diseases, mental health medications, outpatient drugs, overseas drugs, and original research drugs, reflecting a shift in the insurance landscape [1][2] - The insurance scheme has seen a significant increase in claims, with approximately 18 billion yuan paid for innovative drugs in the previous year, a ninefold increase from 2021 [1] - However, the experience of claims varies widely among the 150 million insured individuals, with some facing high out-of-pocket costs due to thresholds and pre-existing conditions [1][6] Group 1: Policy Changes and Trends - The recent notification from the National Financial Regulatory Administration emphasizes the need for commercial health insurance to align premium collection with coverage levels and avoid low-price competition [2] - The 2026 version of "惠民保" has introduced a tiered premium structure, moving away from the previous low-cost model, and has expanded coverage to include more drug categories [2][3] - The number of drugs covered under "惠民保" is expected to reach 672 by 2024, with a significant focus on innovative treatments for cancer and rare diseases [3] Group 2: Coverage Expansion - The 2026 "北京普惠健康保" (Beijing Universal Health Insurance) will cover 87 disease categories and 159 drugs, including new treatments for Alzheimer's and CAR-T therapy [4] - The "齐鲁保2026版" (Qilu Insurance 2026) has expanded its coverage to include 3 high-value medical devices and additional innovative drugs for chronic conditions [4] - Many regions are now including outpatient drugs and original research drugs in their coverage, indicating a trend towards more comprehensive health insurance products [3][4] Group 3: Risk Management and Pricing Strategies - The insurance sector is adopting a risk-based pricing model, allowing for differentiated premiums based on age, health status, and pre-existing conditions [6][10] - The introduction of tiered coverage options aims to balance the need for affordable premiums with adequate benefits, particularly for high-risk groups [6][10] - Recent adjustments have led to increased reimbursement rates for patients with pre-existing conditions, reflecting a shift towards more equitable coverage [8][10] Group 4: Inclusion of New Demographics - The 2026 "惠民保" products are increasingly targeting new citizens and those seeking medical care outside their registered locations, broadening the scope of insured individuals [10][11] - Initiatives to allow family members to share health insurance accounts and to include flexible workers and retirees in coverage are being implemented in various regions [10][11] - The trend towards inclusivity aims to enhance the overall participation rate in the "惠民保" scheme, particularly among younger and healthier individuals [10]

Core Insights - The launch of the "Beijing Universal Health Insurance" for 2026 includes the first and only approved stem cell drug in China, Amy Maitosai Injection, which significantly reduces the financial burden on severe patients by offering up to 65% reimbursement for treatment [1][2] - The inclusion of Amy Maitosai in the special drug directory expands the coverage and depth of advanced biological therapy technologies in the country, facilitating the commercialization process of cell therapy [1] Group 1 - The drug Amy Maitosai Injection is developed by domestic company PlasBio and is indicated for acute graft-versus-host disease (aGVHD) in patients over 14 years old who have failed hormone treatment [1] - aGVHD is one of the most severe complications following hematopoietic stem cell transplantation, with limited traditional treatment options and low long-term survival rates for patients unresponsive to hormone therapy [1] Group 2 - The pricing of Amy Maitosai Injection is significantly lower than its US counterpart, Ryoncil, with a cost of 19,000 RMB per bag compared to 190,000 USD per treatment, making it more accessible [2] - The drug has been rapidly adopted across China, with appointment services available in over 20 provinces, and its distribution covering more than half of the provinces nationwide [2] - Ongoing clinical research is being conducted to expand the indications for Amy Maitosai, targeting difficult-to-treat immune and inflammatory diseases such as diabetic nephropathy and vascular aging, potentially benefiting a broader patient population in the future [2]

Group 1 - Pollon Life, a Chinese stem cell therapy development company, has confidentially applied for a listing in Hong Kong, aiming to raise approximately $300 million [1] - The company is supported by Jack Ma's Yunfeng Capital and is collaborating with Jianyin International, China International Capital Corporation (CICC), and UBS Group to advance its IPO plans, with discussions still ongoing and potential adjustments to the IPO scale and details [1] - Pollon Life, previously known as Platinum Biotech, developed China's first approved stem cell therapy, Aimi Maitosai injection, which is indicated for treating acute graft-versus-host disease primarily affecting the digestive tract in patients over 14 years old who have failed hormone therapy [1]

Group 1 - Pollon Life, a Chinese stem cell therapy development company, has confidentially applied for an IPO in Hong Kong, aiming to raise approximately $300 million [1] - The company has received support from Jack Ma's Yunfeng Capital and is collaborating with Jianyin International, CICC, and UBS to advance its listing plans, with ongoing discussions that may adjust the IPO scale and details [1] - Pollon Life, formerly known as Platinum Biotech, developed China's first approved stem cell therapy, Aimi Maitosai injection, which is indicated for treating acute graft-versus-host disease in patients over 14 years old who have failed hormone therapy [1]

Core Insights - The first and only approved stem cell drug in China, Aimi Maitosai Injection, has made significant progress with its first prescription issued in Beijing, marking the start of its commercial clinical application [1] - The drug, developed by domestic company Platinum Bio, is aimed at treating acute graft-versus-host disease (aGVHD) in patients over 14 years old who have failed hormone therapy [1] - The cost of Aimi Maitosai Injection is approximately 20,000 RMB per bag, significantly lower than similar products in the US, which are priced at 190,000 USD per bag, thus reducing the financial burden on patients [1] Product Development and Market Expansion - Aimi Maitosai Injection has transitioned the treatment of aGVHD from a single-target approach to a multi-target and multi-pathway treatment strategy [1] - The drug's service has achieved nationwide coverage in China, facilitated by strategic partner Alibaba Health, with appointment services available in over 20 provinces including Beijing, Shanghai, and Guangdong [1] - Ongoing research is being conducted to expand the drug's indications to include diabetic nephropathy, acute kidney injury, and vascular aging, potentially broadening its application in various disease areas [1]